CTCs Detected Lung Cancer Recurrence Before PET/CT
In this video we discuss a new study that tested the feasibility of using circulating tumor cells to detect recurrence in patients with locally advanced non–small-cell lung cancer.
In this video, Chimbu Chinniah, a research fellow at the University of Pennsylvania, Philadelphia, discusses the results of a new study that examined the feasibility of using circulating tumor cells (CTCs) to detect recurrence in patients with locally advanced non–small-cell lung cancer (NSCLC). He also highlights some of the advantages of CTCs compared with tissue biopsies or scans, and reviews a particularly striking case.
The study included 48 NSCLC patients who were ineligible for surgery and underwent chemoradiotherapy for their disease. Blood samples were drawn prior to treatment initiation, during treatment, and then following treatment cessation. CT or positron emission tomography (PET)/CT scans were obtained every 3 months.
Chinniah presented the results (abstract 3) at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco.
Imaging scans used with permission.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
